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Methods: Leptomeningeal metastases (LM) in the setting of glioma have often been
thought to carry a particularly poor prognosis. We sought to better characterize this phe-
nomenon through a review of patients with glioma seen in our institution over the preceding
10 years. We focus here on 34 cases with LM due to grade III or IV glioma. Over the period
in question, we estimate a prevalence of almost 4% in those affected by grade IV tumors.
Results: Leptomeningeal spread was present at the time of initial diagnosis in 4 patients.
Among the others, LM occurred at the time of first progression of disease in 17. The
median time to development of LM (excluding those where it was present at initial diagno-
sis) was 16.4 months [95% confidence interval (CI) 8.2–43.9]. The median time to further
progression of disease following LM was 4.9 months (95% CI 3.1–6.9).Twenty-five patients
were known to have died at the time of writing. Thus, median overall survival (OS) was
10.2 months (95% CI 8.8–14.7) following LM. At the time of diagnosis of LM, some form
of treatment (chemotherapy and/or radiation vs. no treatment) increased OS (median 11.7
vs. 3.3 months, p<0.001 by log-rank test). Use of radiation therapy (vs. no radiation) also
increased OS, although the effect was more modest (7.8 vs. 16.8 months, p=0.07). Higher
Karnofsky Performance Status (KPS) at the time of diagnosis of LM was associated with
OS (p=0.007, median OS for KPS ≥90 19 months vs. 7.8 for KPS <90). In a two-variable
model incorporating the use any treatment (vs. none) and KPS, the latter tended to be a
more significant predictor of survival (p=0.22 vs. p=0.06 by likelihood-ratio test). This
was also true for radiation (vs. none) and KPS (p=0.27 vs. p= 0.02). No significant benefit
could be demonstrated for the use of chemotherapy considered alone, either systemic or
intrathecal. It should be noted that 4 of 9 patients receiving intrathecal chemotherapy had
a ventriculo-peritoneal shunt in place during these injections, which may have reduced its
effectiveness.
Conclusion: Overall, treatment appears to improve outcomes. We favor maximal treat-
ment, as tolerated, particularly with a KPS of ≥70. Such treatment would typically
include radiation to the maximum tolerated dose, concurrent, and adjuvant chemotherapy
(preferably with an alkyating agent), in addition to intrathecal treatment.
Keywords: glioma, glioblastoma multiforme, leptomeningeal, metastases, Ommaya, intrathecal
1. INTRODUCTION
Malignant glioma (in this series grade ≥grade III) with lep-
tomeningeal metastases (LM, also known as leptomeningeal dis-
ease or meningeal gliomatosis) has generally been considered a
rare and serious condition. No consensus on treatment currently
exists. As far as we are aware, this is the largest case series to date
addressing this topic.
There are already a number of case reports and small case
series describing various approaches to treatment. One series
noted promising results with use of thioTEPA (1), while another
suggested that Palliative Care may be preferable to intrathe-
cal chemotherapy (2). One case report suggested that liposomal
cytarabine may be of value, with a reported time to progression
(TTP) of 6 months (3). In cases, where LM is present at the time
of first diagnosis, the use of radiation and temozolomide has been
advocated (4).
In the present series, we began by identifying all cases of LM
from glial tumors in our institution. By this process, we estimated
the prevalence of the condition. We sought to characterize the
development of LM and to determine which factors are important
in its genesis. We aimed to describe the characteristic findings at
the time of diagnosis – clinical, radiographic, and of cerebrospinal
fluid (CSF).
Our principal question was whether any of the standard modal-
ities (chemotherapy, including intrathecal, and radiotherapy) pro-
posed for treatment of this condition could be shown to influence
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TTP or overall survival (OS) following the diagnosis of LM. We
also addressed whether the patient’s performance status might be
more important than any of the above treatments.
Based on our work, we offer suggestions for diagnosis and treat-
ment of LM. We also place the current work in the context of
previous similar studies.
2. MATERIALS AND METHODS
We reviewed the records of our weekly Multidisciplinary Cen-
tral Nervous System Tumor Conference from 2003 to 2013
(n= 12,477) for patients with glioma who had LM. We ini-
tially included pediatric cases (i.e., age <18) and grade II tumors
(including two cases of ependymoma, one myxopapillary). It has
been proposed that ependymoma shares a common precursor with
glial tumors (5). On reflection, we decided to focus the review on
adult patients with grade III and IV tumors in order to minimize
heterogeneity.
This work was approved by the Institutional Review Board at
St. Joseph’s Hospital, to which the Barrow Neurological Institute
is affiliated.
Clinical information was obtained through a review of the
available records at St. Joseph’s Hospital. These included visit notes
in addition to radiological and pathological data. Relevant labo-
ratory results were reviewed as well. Imaging characteristics were
established through a consensus of two reviewers. In some cases,
complete information was unavailable as some patients followed
up at outside institutions, either prior to or after their diagnosis.
Throughout the chart review, variables considered to have pos-
sible value were identified. The complete dataset is available as
supplementary material. This shows all of the variables considered
herein.
Analysis was performed using R version 3.0.1 (2013-05-16) (6–
10). This is open-source software for statistical analysis which has
been validated for use in clinical practice (11).
For measures of a proportion (e.g., 5/10), a 95% a confi-
dence interval (CI) is generally given when the measure first
appears. Although perhaps unnecessary, we include these con-
fidence intervals to illustrate the uncertainty that arises when
dealing with small numbers of patients. These confidence inter-
vals are generally wide given the modest number of observations
involved. They are derived using a Jeffreys prior. This is a Bayesian
method using a minimally informative prior beta distribution and
is considered to have optimal coverage properties for this type
of CI (12).
Given the small sample size, a significance or p-value of ≤0.1
was considered worth highlighting. As the sample size decreases,
p-values tend to become larger (unless the null hypothesis is true).
Thus, when working with such small numbers of observations,
a more generous margin that the typical p≤ 0.05 was felt to
be reasonable. This is particularly the case in the context of an
exploratory (hypothesis generating) analysis.
The mainstay of survival analysis was the Cox proportional-
hazards model. In order to assess the effects of a given predictor,
we generally used the log-rank test (LRT). In cases where this was
close to the margin of significance, we also looked at the likelihood-
ratio (LiRT) and Wald tests. All of these test, the significance of a
given predictor and should be concordant.
The magnitude of an effect is given as the hazard ratio (HR).
This is the multiplier of the “baseline” risk of progression or death
given the effect of a predictor.
The only continuous predictor in the Cox models was age. We
considered this to be a linear scale.
In cases where all subjects progressed, we also used the Mann–
Whitney–Wilcoxon (or Mann–Whitney U) test (two-sided). This
is a non-parametric test, which compares groups based on the
ordering of a variable (e.g., the time to progression). The results
should closely approximate the other tests of significance for a Cox
model where no censoring is present.
When comparing the survival of more than two groups (e.g.,
performance status and treatment considered together), we also
used the log-rank test for trend. This is designed to detect ordered
differences in survival curves; that is, at least one group has a sur-
vival advantage compared to the next-worst group (in terms of
survival). We also used the standard log-rank test, which estimates
whether all curves have equal survival.
With such small numbers, we felt that two variables at most
could be included in Cox models. We did not consider interactions.
Our only ordinal variable was the Karnofsky Performance Sta-
tus (KPS). Here, we used Kendall’s tau (KT) to test for association.
This was thought to be fairer than considering KPS as continuous.
Clinically, a drop from 80 to 70 cannot be equated with a drop
from 70 to 60. Similarly, when using the KPS in Cox models, we
preferred to include it as an ordinal scale when possible.
3. RESULTS
We initially identified 41 cases; these are shown in Table 1, listed
by grade and then by time to death. As above, we excluded those
age<18 when LM was diagnosed, those with grade II tumors and
those where the grade was uncertain. This left 34 subjects, who are
the subject of the remainder of the paper.
These patients ranged in age from 19 to 66 years (median 49)
at this time. The primary tumor was glioblastoma multiforme
(GBM or grade IV glioma) at this time in 24 of 34 patients (71%,
CI 54–84).
3.1. FROM INITIAL DIAGNOSIS TO DEVELOPMENT OF LM
At the time of initial tumor diagnosis, 4 of 34 (12%, CI 4–26) had
LM.
In the others, the TTP from initial diagnosis ranged from 2.8 to
221 months (median 16.4). In this group, LM were present at the
time of the first progression of disease in 17 of 30 patients (57%,
CI 39–73).
In five cases, the primary disease had progressed from a lower
to a higher grade. In four cases, oligodendroglioma (grade II)
progressed to the anaplastic form (grade III). Another progressed
from oligoastrocytoma (grade II) to GBM (grade IV).
In six cases LM was discovered more than 5 years after the tumor
was first diagnosed. These are shown in Table 2.
In one-variable Cox models, advancing age was associated with
earlier progression (10-year increase, HR= 1.6, p< 0.005).
Cases where the original pathology was GBM were more likely
to progress rapidly (HR 5, p< 0.0005 by LRT and Wilcoxon test,
median 7.9 vs. 48.6 months). These patients were generally older
(median 50 vs. 30 years, Wilcoxon p= 0.003).
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Table 1 | Summary of patients initially identified (n=41).
Age Gender Time to LM Pathology (at time of LM) Treatment Time to progression Time to death Died?
39 f 24.2 GBM None NA 0.1 No
47 m 2.8 GBM None NA 0.4 Yes
53 m 5.0 GBM i.t.+RT 0.8 1.2 NA
58 f 3.9 GBM None NA 1.3 Yes
58 m 8.5 GBM None NA 1.4 No
15 m 27.1 GBM None 0.8 2.1 Yes
41 m 14.5 GBM None NA 3.3 Yes
20 m 7.9 GBM i.t.+CT+RT 1.3 4.1 Yes
51 f 16.4 GBM RT NA 4.5 NA
42 m 141.3 GBM CT 5.0 5.9 No
56 m 69.5 GBM i.t.+CT NA 6.4 Yes
57 m 5.1 GBM CT 1.4 7.4 Yes
66 f 5.6 GBM None 3.9 7.8 Yes
57 f NA GBM CT+RT 2.4 8.8 Yes
59 m 16.3 GBM sx+ i.t. 7.4 9.7 Yes
53 m 7.8 GBM CT+RT 4.7 9.9 Yes
50 f 8.2 GBM CT 9.1 10.0 Yes
32 f 5.1 GBM i.t.+CT 5.3 10.2 Yes
62 m 3.2 GBM CT 5.5 11.7 Yes
26 m NA GBM NA NA 13.6 Yes
23 f 45.2 GBM CT+RT 9.0 14.4 Yes
47 m 0.0 GBM RT 1.6 14.7 Yes
55 f NA GBM CT+RT 6.3 20.2 Yes
19 f 4.9 GBM RT 6.9 23.5 Yes
41 m 39.6 GBM i.t.+RT+CT 4.4 32.3 Yes
31 m 65.4 AOA None NA 1.0 No
32 f 91.7 AO i.t.+RT 1.4 2.2 No
32 f 92.1 AO i.t. NA 2.4 No
33 m 18.0 AG CT 3.0 4.7 Yes
41 m 43.9 AOA i.t.+CT NA 6.2 Yes
19 m 10.0 AA NA NA 9.1 No
40 m 37.0 AO CT 6.3 13.5 Yes
58 m 220.8 AO CT+RT 3.1 18.9 Yes
33 m 48.6 AO sx+ rt+ ct 9.4 19.0 Yes
51 f 43.2 AO CT 22.3 42.0 Yes
41 f 83.4 OA sx+CT 5.2 5.9 No
51 m 21.6 ME rt NA 38.4 No
18 m NA EP CT+RT 62.8 75.0 No
31 f 30.4 NA NA NA 1.7 No
35 f 39.7 Astro CT 16.6 22.5 No
3 m 1.2 Astro NA NA NA NA
Sorted by pathologic grade and then by time to death.
Times are given in months.
Age is at time of first diagnosis.
LM, leptomeningeal metastases.
Pathology: GBM, glioblastoma multiforme; AOA, anaplastic oligoastrocytoma; AO, anaplastic oligodendroglioma; AG, anaplastic glioma (anaplastic PXA vs. anaplastic
ganglioglioma); AA, anaplastic astrocytoma; OA, oligoastrocytoma; ME, myxopapillary ependymoma; EP, ependymoma; astro, astrocytic tumor; grade unknown (grade
II, III or IV).
Treatment: i.t., intrathecal (via Ommaya); CT, chemotherapy; sx, surgery; RT, radiotherapy (intensity-modulated radiation therapy and/or stereotactic radiosurgery).
NA, not available.
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Table 2 | Cases of LM occurring >5 years after initial diagnosis.
Age Gender Location Pathology (at initial diagnosis) Pathology (when LM) Progressions Time to LM (months)
50 m t+o GBM GBM NA 69.5
28 m f AOA AOA 3 65.4
40 m f AO AO 2 220.8
25 f f O AO 4 91.7
20 f f O AO 3 92.1
30 m f O vs. OA GBM 4 141.3
Sorted by pathologic grade and then by time to LM.
Age – age at initial diagnosis.
Location (of primary tumor): t+o, temporal+occipital; f, frontal; Pathology: GBM, glioblastoma multiforme; AOA, anaplastic oligoastrocytoma; AO, anaplastic oligo-
dendroglioma; O, oligodendroglioma; O vs. OA, oligodendroglioma vs. oligoastrocytoma; Progressions, number of progressions (after intial treatment) before LM
diagnosed. These were diagnosed clinically and prompted a change in treatment.
NA, not available.
Cases centered in the temporal lobe were also more likely to
progress rapidly (HR 3.8, p= 0.01 by LRT, p= 0.03 by Wilcoxon
test, median 6.7 vs. 45.9 months). These were more likely to be
GBM (Wilcoxon p= 0.03).
The 1p19q co-deletion was tested in 4 patients. It was present in
one case of oligodendroglioma. This case took longer to progress
than the others (92.1 months vs. median of 23.5 months), although
this did not reach significance.
There was only one patient who received no chemotherapy or
radiation at the time of diagnosis; this person progressed slightly
sooner (14.5 months vs. median of 16.3 months).
The following factors did not reach significance based on the
LRT: gender, location in basal ganglia vs. lobar, laterality (left
vs. right and unilateral vs. bilateral), MIB-1 (including MIB-1
<10 vs. ≥10%), MGMT via immunohistochemistry (including
MGMT< 50% vs.≥ 50%), extent of surgery (including gross vs.
subtotal resection), use of standard radiation (60 Gy intensity-
modulated vs. none), and chemotherapy (some vs. none and also
temozolomide vs. none). There were two patients who received the
radiation sensitizer motexafin in addition to standard radiation;
this also did not predict time to LM vs. those receiving standard
radiation.
We recognize the shortcomings of immunohistochemistry in
determining MGMT status. While this is a widely employed and
relatively simple test, methylation-specific PCR remains the “gold
standard” when available (13).
3.2. SYMPTOMS, SIGNS, AND RESULTS WHEN LM DIAGNOSED
3.2.1. Symptoms
Symptoms at onset of LM documented in more than one patient
are shown in Table 3.
The patient’s KPS had a tendency to decrease when LM were
diagnosed. In 17 cases, where this metric was recorded before (i.e.,
within 3 months) and after (i.e., within 1 week) diagnosis it fell
from 0 to 60 points (median 10). Drops in KPS of ≥10 (or ≥20)
were not related to the prior KPS (KT).
3.2.2. Imaging
Magnetic resonance imaging (MRI) when LM were diagnosed
revealed that proximity of tumor to CSF is crucial to spread.
Table 3 | Common symptoms at time of LM.
Symptom Frequency (%) 95% CI
Headache 53 37–69%
Gait disturbance 29 16–46%
Nausea 21 10–36%
Pain 18 8–33%
Confusion/altered mental status 18 8–33%
Sorted by frequency.
CI, confidence interval.
Proximity to a lateral ventricle, in particular, was present in 16
of 32 (50%, CI 33–67) cases with information available.
Other putative origins (each present in at least two patients,
and presented in order of frequency) were adjacent to the follow-
ing locations: the cerebral cortex, the superior temporal sulcus, the
transverse fissure, and the central sulcus. In some cases, tumor was
present in more than one of the aforementioned locations.
MRI of the whole spinal cord was performed in 12 of 34 (35%,
CI 21–52) patients and another two had at least some imaging
of the cord. In those undergoing imaging of the whole cord, 9 of
12 (75%, CI 47–92) had symptoms suggesting myelopathy. In the
remaining three cases, imaging appears to have been undertaken
as a screening exam.
Spread of LM was seen on MRI in 28 of 33 cases with informa-
tion available (85%, CI 70–94). Common sites included the cortex,
occurring in 16 cases (48%, CI 32–65), spine in 5 (15%, CI 6–30),
and cauda equina in 4 (12%, CI 4–26).
The spread to spinal cord (and brainstem in some cases) is
not surprising given the normal direction of flow of CSF. More
striking is that in eleven cases with spread to the cortex, a corti-
cal fissure was the putative origin of cells in seven. The superior
temporal sulcus was implicated in five cases and the transverse
fissure and superior pre-frontal sulcus in one each. This suggests
that flow of CSF from these locations tends to proceed toward the
cortex. Examples of this are shown in Figures 1A,B. While intu-
itive, to our knowledge this phenomenon has not previously been
described.
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FIGURE 1 | MRIs (1.5T,T1-weighted, post-contrast). (A) GBM with local
spread to the right superior temporal sulcus. Further spread rostrally along
the juxta-cortical leptomeningeal space is present. (B) GBM with local
spread to the right transverse sulcus. Further spread rostrally along the
juxta-cortical leptomeningeal space can also be seen. (C) A small focus of
GBM in the right temporal lobe with spread to the right middle temporal
sulcus, then rostrally along the subarachnoid space on the right. A second
focus is seen in the left middle frontal gyrus. This is likely to have spread
through the leptomeningeal space. (D) GBM with spread to dura at C5–6
and minimal intramedually invasion. Intrathecal chemotherapy is unlikely to
penetrate this fully and flow caudally is likely to be impaired.
In one unusual case, the tumor appears to have spread from
a focus next to the middle temporal sulcus to the contralateral
frontal lobe, seen in Figure 1C. Prior to developing this distal
spread, the small contralateral focus was the only site of active
disease. While intra-parenchymal spread from one location to
the other cannot be excluded, spread through the leptomeningeal
space appears more plausible.
Other representative findings on MRI are shown in Figure 2. In
some cases, the findings were subtle as illustrated in Figures 2C,D;
these images were taken from the same patient. The presence of
tumor next to the lateral ventricle is the probable origin of cells.
Spread to a cortical fissure was only apparent on sagittal imaging.
3.2.3. CSF
The result of analysis of CSF at time of diagnosis is shown in
Table 4. The initial CSF was taken from an Ommaya reservoir
in 5 of 16 cases (31%, CI 13-56). In these cases, the diagnosis
had already been made on clinical and radiographic grounds; CSF
from a lumbar puncture was not considered essential for confir-
mation. The CSF from the Ommaya thus served as a “baseline,”
which could be used as an adjunct in monitoring response to
treatment.
FIGURE 2 | MRIs (1.5T,T1-weighted, post-contrast). (A) GBM spread
along cerebral cortex and caudally to brainstem. (B) GBM with spread to
interhemispheric fissures and a new parenchymal focus in the contralateral
hemisphere. (C) GBM adjacent to left lateral ventricle. (D) Leptomeningeal
spread from (C) to a cortical sulcus on the same side.This was not apparent
on axial imaging.
Table 4 | CSF results at time of diagnosis.
Ommaya
No Yes
WBC 27±13.2 1.0±0.6
Lymph 56.1±13.7 53.3±20.0
MØ 49.2±15.0 NA
Protein 441±181 80.7±21.5
Glucose 65.8±6.4 76.0±7.4
Cytology 0/2 3/9
Values are given as mean± standard error.
Cytology is no. positive/total no.
WBC, white blood cell count (corrected for red cells); Lymph, lymphocytes (% of
WBC); MØ, macrophages (%); NA, not available.
Protein and glucose measurements are given in mg/dLt.
The high proportion of macrophages in most samples obtained
by lumbar puncture is notable, a finding more classically associ-
ated with intracerebral hemorrhage and with fungal infections of
the CSF (14).
3.3. INITIAL TREATMENT OF LM
Referral for Hospice care took place in 6 of 33 patients (18%, CI
8–34) at the time of diagnosis of LM. These patients tended to
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have a lower KPS (p< 0.01, KT). There was no association with
age or pathology (GBM vs. others).
Two patients were lost to follow up following diagnosis. Some
form of treatment was attempted in all of the others (n= 24), with
the exception of one other whose course was complicated by a hip
fracture shortly after diagnosis.
Some form of treatment was clearly beneficial for OS (HR= 0.1,
p< 0.001, median 11.7 vs. 3.3 months), although no effect could
be shown on TTP. This is shown in Figure 3A. Those receiving
treatment tended to have a higher KPS (Wilcoxon p= 0.02).
3.3.1. Systemic chemotherapy
Systemic chemotherapy was given to 18 of 24 patients (75%, CI
56–89). Of those receiving temozolomide, the standard Stupp pro-
tocol was used in 14 (15). Another patient received a “dose dense”
regimen of 75 mg/m2 daily. In one patient, information on the
type of chemotherapy was not available. No effect of systemic
chemotherapy could be demonstrated on OS or TTP.
The remaining patients were treated with regimens involv-
ing bevacizumab, one in combination with irinotecan, the other
with carboplatin. (This latter had already previously been on
single-agent bevacizumab).
3.3.2. Intrathecal chemotherapy
Intrathecal chemotherapy via Ommaya was given in 9 of 24
cases (38%, CI 20–57). In five cases Depocyt® (liposomal cytara-
bine 50 mg q 2 weeks) was administered. Three others received
methotrexate (15 mg twice/week) and in one case the type of
treatment was not available.
Only three of nine managed at least 6 weeks of treatment before
further progression. The longest duration of treatment was a
patient on liposomal cytarabine for 14 weeks.
A caveat here is that three of five patients receiving Depocyt and
one of three of those on methotrexate had a ventriculo-peritoneal
(V-P) shunt in place for at least some of the time that they were
on treatment.
Overall, 10 patients had a V-P shunt placed. In six cases, the
shunt was placed before LM was diagnosed (median 2.3 months
prior to diagnosis with the longest being 44.2 months).
3.3.3. Radiotherapy
Radiotherapy was given to 14 of 24 patients (55%, CI 39–76). In
five, focal spinal disease was targeted (one using CyberKnife®). In
one, radiation of most of the spine was performed. Disease in the
brain was targeted with whole-brain radiation in two cases (one
of which was stopped early due to rapid deterioration), posterior
fossa radiation in one and Gamma Knife® in another.
Radiotherapy improved OS (HR= 0.5, p= 0.07, median 16.8
vs. 7.8 months), although no effect could be shown on TTP. This
is shown in Figure 3B.
3.3.4. KPS
Karnofsky performance status at time of diagnosis ranged from
60 to 100 (median 70) in those not referred for Hospice care. KPS
predicted improved TTP (HR= 0.7 for 5-point increase on lin-
ear scale, p= 0.04; p= 0.09 when considered as ordinal scale).
It also predicted OS (HR= 0.7 for 5-point increase on linear
FIGURE 3 | Kaplan–Meier plots showing time to death (months).
Dotted lines show 95% confidence intervals for the curves. (A) Use of any
treatment (vs. none). (B) Use of radiation (vs. none).
scale, p= 0.007; p= 0.001 as ordinal). A marked difference was
established for a KPS of ≥90 (HR= 0.15, p= 0.03, median 19 vs.
8 months). This is shown in Figure 4A.
Last KPS measured prior to diagnosis of LM also predicted OS
(p= 0.01 as ordinal).
3.3.5. Spinal metastases
Spread to the spinal cord occurred in 10 cases. There was no asso-
ciation with KPS or presence of GBM. These patients tended
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FIGURE 4 | Kaplan–Meier plots showing time to progression
(A) or death (B) in months. Dotted lines show 95% confidence intervals
for the curves. (A) KPS ≥90 (vs. <90). (B) Spinal spread visible (vs. none).
to progress more quickly (HR= 2.7, p= 0.04, median 2.4 vs.
5.5 months). This is shown in Figure 4B. However, spinal metas-
tases did not affect OS. Most of these patients received radiation
(chi-square p= 0.004).
3.3.6. Other predictors of progression following initial treatment of
LM
Age, gender, and pathology (including GBM vs. others) showed no
significant effect on TTP or OS on one-variable Cox models (and
Wilcoxon test as appropriate).
FIGURE 5 | Kaplan–Meier plot showing time to death (months) with
respect to KPS (≥90 vs. <90) and the use of any treatment (vs. none).
Dotted lines show 95% confidence intervals for the curves. The test for
trend is designed to detect ordered differences in survival curves.
3.3.7. Two-variable models
When considering the effects of KPS and radiation on OS, neither
the overall model nor either coefficient was significant (p= 0.1 by
LiRT for model).
Karnofsky performance status was a more important factor
than the effect of any treatment (vs. none) when both were con-
sidered together (LiRT p= 0.01 vs. p= 0.45, Wald p= 0.03 vs.
p= 0.43). A graph of this is shown in Figure 5.
3.3.8. GBM considered alone
A sub-analysis was performed focusing only on those with GBM
at the time of diagnosis of LM (n= 24). Male patients were more
likely to progress rapidly (HR 2.8, LRT= 0.06), although this did
not affect OS. Some form of treatment was useful in increasing
OS (HR= 0.09, LRT= 0.0003), although treatment was associ-
ated with better KPS (Wilcoxon p= 0.03). When considering both
together, KPS was a more significant predictor of OS (p= 0.01 by
LiRT vs. p= 0.97).
3.4. TREATMENT FOLLOWING PROGRESSION OF LM
At the time of progression after LM, 20 of 29 (69%, CI 51–
83) patients with information available received some additional
treatment. In these 20 patients, the median time to death was
10.2 months (95% CI 9.7–20.2).
Only one additional form of treatment was attempted in 14
of 20 patients (70%, CI 43–86). Nonetheless two cases (one with
GBM, the other AO) survived long enough to receive four changes
in treatment (i.e., they progressed and changed to a new treatment
four times).
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Table 5 | Series reporting survival in patients with LM treated with i.t. chemotherapy.
Series n GBM% CT% RT% i.t.% i.t. type mPFS mOS
Dardis (current) 34 71 56 44 28 liposomal cytarabine/MTX 4.9 10.2
Chamberlain (2) 18 44 72 61 100 MTX⇒Ara-C⇒ thioTEPA 3 3.5
Witham et al. (1) 14 64 36 71 100 thioTEPA NA 10
Yung et al. (16) 12 75 0 0 8 MTX+Ara-C NA 11.3
i.t.%, % receiving intrathecal CT; mPFS, median progression-free survival; mOS, median overall survival; MTX, methotrexate; Ara-C, cytarabine (cytosine arabinoside);
NA, not available.
4. DISCUSSION
Our series suggests a benefit to treatment in selected patients
with this condition, particularly radiation treatment. The prin-
cipal weakness of the current study is the heterogeneity of disease
severity and of the treatments employed. The wide variation in
performance status makes the effects of treatment difficult to dis-
cern in such a small sample. This is further complicated by the
natural selection bias that occurs when deciding on treatment for
such sick patients (Almost 20% were referred for Hospice care at
the time of diagnosis.). These same problems make the design of
clinical trials for this condition particularly challenging.
4.1. COMPARISONS TO OTHER CASE SERIES
Two similarly sized series have reported results of use of intrathe-
cal chemotherapy for this condition (1, 2). These, along with an
earlier series, are summarized in Table 5. It is striking that the
median OS time in the earliest series, from 1980, is better than our
current series, yet only one patient received treatment [with i.t.
chemotherapy (16)]. However, in this latter 4 of 12 patients were
diagnosed only at autopsy, whereas all of ours had symptoms or
signs leading to diagnosis ante mortem.
It appears that LM occurring in those with GBM should be
regarded as more aggressive than that stemming from lower-grade
gliomas. Our patients with GBM had a median OS (from time of
diagnosis of LM) of 9.9 vs. 18.9 months for the grade III tumors,
although this did not reach significance. This finding is in keep-
ing with the series from Witham et al. (1), which also reported a
shorter survival for those with GBM.
Reported cases of spinal metastases from GBM in this setting
have already been the subject of a review [n= 24 (17)]. In 37
patients with available survival data, the mean survival time was
reported to be 3.7 months (range 0.1–12). We had five patients
with GBM, LM, and spinal involvement, with a median OS of
9.9 months, which was not significantly different from those with-
out spinal involvement. In the series from Lawton et al. (17),
chemotherapy was used in 14% of cases, with radiotherapy in
77%. Intrathecal chemotherapy was not used in any of these cases.
In keeping with earlier series focusing on those with dissemina-
tion to the spinal cord, all of our cases had a clear source of com-
munication with CSF (18). Also consistent with data presented
in this series, patients with spinal cord involvement experienced
a relatively short time to further progression (median 2.4 months
in our 7 patients). Another review, (n= 19), focusing on spinal
metastases reported a mean OS time of 4.5 months, also shorter
than in our series (19).
Radiation with temozolomide has been advocated as the treat-
ment of choice in cases where LM is present at the time of first
diagnosis (4). This was based on a review of 15 cases. One patient
survived 22 months from diagnosis with this treatment. The 6
patients in our series treated in this way did reasonably well with
a median PFS of 4.6 months and median OS of 18.9 months.
4.2. ESTIMATES OF PREVALENCE
Symptomatic LM has traditionally been considered rare. In the
case of GBM, rates of 2–3% have been reported (20, 21). However,
symptomatic LM may occur in up to 19% of cases of GBM involv-
ing the cerebellum (22). We estimate that our institution sees c. 60
cases of newly diagnosed GBM per year. Thus per our calculations,
over 10 years c. 3.8% of patients experienced this complication,
which is broadly in agreement with the above figures.
However, the rate of LM in gliomas may be underestimated
as autopsy series report rates in the range of 20–25% (16, 23,
24). It is likely that we are underestimating the true rate, as no
autopsies were performed the patients in our series. One series
where all patients underwent autopsy reported ante mortem diag-
nosis in only 8 of 12 patients (16). Generally speaking, the rate of
autopsy appears to be falling over time: for example in the USA
this decreased from 19 to 9% over the period 1972–2007 (25).
4.3. TIME TO DEVELOPMENT OF LM
The findings that the time to development of LM appears shorter
in older patients and in patients with GBM (vs. grade III tumors)
are not unexpected. More striking is the association with an initial
location in the temporal lobe. We attribute this to its close proxim-
ity to the superior temporal sulcus, the transverse fissure, the cen-
tral sulcus, and the lateral ventricle. These all appear to be common
conduits for the dispersion of malignant cells into the CSF.
While time to development of LM was generally short, it is
striking that is isolated cases this can occur many years after the
initial diagnosis. This phenomenon appears to be associated with
evolution of the tumor to a higher pathologic grade.
4.4. SUGGESTIONS FOR DIAGNOSIS
A summary of recommendations is shown in Box 1.
The diagnosis of LM is ultimately clinical. Support is typically
sought from imaging and CSF. Occasional cases are diagnosed on
the basis of imaging without any new signs or symptoms. Positive
CSF cytology, while sufficient, is not essential for diagnosis. In the
appropriate context, CSF may increase the “post-test” probabil-
ity of diagnosis. Establishing “baseline” CSF results at the time of
diagnosis is worthwhile as this allows the clinician to monitor the
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Box 1 Diagnosis of LM.
• Clinical: suspicious symptoms/signs, particularly hydrocephalus
• Radiographic: MRI brain+whole spine with contrast
• CSF: cytology; cell count, protein, glucose
response to treatment. A low threshold for further investigation is
warranted once the diagnosis of LM is entertained in the setting
of glioma. This is particularly the case where the original tumor
location is in close proximity to CSF.
The need for placement of a CSF shunt (particularly where
no clear mechanical obstruction is present) should always prompt
consideration of LM. In one series of 12 such patients, 10 showed
evidence of hydrocephalus (16). Interestingly, in a series of 7
patients with communicating hydrocephalus in the context of
GBM, none showed MRI changes typical of LM (26). In this latter
series CSF cytology was generally normal, although protein was
typically elevated. The authors suggest that initial post-operative
radiation may cause fibrosis of the arachnoid granulations leading
to blockages by protein released at the time of a second surgery.
We saw no evidence of such an association (Fisher’s exact test),
suggesting that LM itself is likely to be the more important cause
in most patients. Given that some form of treatment is valuable
for LM, this makes the investigation of hydrocephalus all the more
important not to overlook in those with glial tumors.
Intractable nausea/vomiting should lead to a high degree of
suspicion of LM (27). We only had three patients with disease
affecting the 4th ventricle; two presented with nausea.
Complete spinal imaging (MRI+ contrast if possible) should
be done when practical. Although the majority of the patients in
our series who underwent spinal imaging had symptoms, which
suggested spinal involvement, it is likely that some cases of addi-
tional asymptomatic disease would thereby be uncovered, which
may lead to changes in management. In particular, focal radiation
to asymptomatic spinal LM appears a reasonable strategy. Accord-
ing to at least one case report, FDG-PET may also be useful in this
setting (28).
4.5. SUGGESTIONS FOR TREATMENT
Being a rare complication of an uncommon disease, this prob-
lem is unlikely to be the subject of prospective trials without
multi-institutional co-operation. For the present, management is
individualized and generally guided by retrospective series such as
this. A summary of strategies is shown in text Box 2.
Overall, treatment appears to improve outcomes. We favor
maximal treatment, as tolerated, particularly when the KPS is
≥70. This would typically involve radiation to the maximum toler-
ated dose, while avoiding damage to surrounding structures. The
dosing is individualized and based primarily on prior radiation
exposure. For the spinal cord, focused (e.g., intensity-modulated)
approaches are preferred. For first treatment, doses of 40–50 Gy
may be employed. As a rule, we prefer to avoid irradiation of
the entire spinal cord, given the risk of myelosuppression. For the
brain, whole-brain radiation is typically employed, with first doses
in c. 30 Gy. In individual cases the posterior fossa alone may receive
treatment, or be given an additional boost.
Box 2 Treatment of LM.
• Radiation
• Brain: whole-brain 30 Gy; consider focal or additional dosing
to posterior fossa
• Spine (focal): intensity-modulated 40–50 Gy
• Concurrent daily temozolomide 75 mg/m2 as tolerated
• Adjuvant chemotherapy: e.g., alkylator (temozolomide, lomus-
tine)+bevacizumab
• Intrathecal (via Ommaya): typically liposomal cytarabine
The use of radiation does appear to improve OS. However, a low
KPS following diagnosis of LM may outweigh any intervention,
particularly in the case of chemotherapy.
Regarding radiation, focal clumps of cells may impair the flow
of CSF, thus limiting the penetration of intrathecal chemother-
apy, rendering treatment via Ommaya ineffective. An example
of this is offered in Figure 1D. This may be formally assessed
using a radioisotope as per (29) although we are not routinely
implementing this technique.
Systemic chemotherapy is also individualized and depends pri-
marily on prior treatment. If radiation is to be employed, it appears
rational to combine this with an alkylating agent with good CSF
penetration, typically temozolomide. Adjuvant systemic treatment
will typically involve an escalation or change in approach, e.g., the
addition of bevacizumab to temozolomide or for those already on
this combination, a change from temozolomide to lomustine.
Toxicities from intrathecal (i.t.) treatment described in the
series by Chamberlain (2) were much higher than in our series
with 12 of 18 developing aseptic meningitis. The authors’ sugges-
tion of a palliative approach to these patients is understandable
in this context. By contrast, Witham et al. (1) suggest their results
are promising and that i.t. treatment should be considered for all
patients.
Regarding liposomal cytarabine, while no definite benefit can
be attributed to its use our series, at least one case report shows
some evidence of benefit and it is generally well tolerated (3).
The reported TTP of 6 months in the cited case is similar to that
of five patients in our series receiving this treatment, who had a
median TTP of 4.4 months. This may be started concurrently with
radiation.
4.5.1. Certain caveats apply
In our patients receiving liposomal cytarabine with an Ommaya,
three of five also had a V-P shunt (located in a lateral ventricle). In
such cases, persistence of the instilled agent in CSF is likely to be
shorter. Currently, we employ a strategy of turning off the shunt
prior to instillation (where possible) and leaving it off for most of
1 day (or longer if possible, typically if the patient is in hospital and
can be monitored). Placement of the Ommaya in a basal cistern is
another rational approach.
Another consideration should be the inconvenience of travel
(for the patient) for an instillation; this can be significant for an
agent like methotrexate,which is administered twice/week. For this
purpose, we are investigating the possibility of training a caregiver
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in the use of chemotherapy. Such an approach has already been
shown to be practical for intravenous antibiotics (30).
5. CONCLUSION
Leptomeningeal spread of glioma, while often considered calami-
tous, does not necessarily mean that treatment should be aban-
doned. The treatments proposed above are relatively benign and
in most cases, the benefits are likely to outweigh the side-effects
and inconvenience. The patient’s performance status is vital in
individualizing decisions.
SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found online
at http://www.frontiersin.org/Journal/10.3389/fneur.2014.00220/
abstract
Data Sheet 1.pdf | Shows the R code used for analysis.
Data Sheet 2.csv | Shows the dataset from which the results were
generated.
Data Sheet 3.csv | Shows the key to Data Sheet 2 (column names,
abbreviations and explanations).
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